BioCEP

Company Overview

Snapshot

Founded in July 2006, BioCEP operates with 1–10 employees. The company has raised $6.83M across two funding rounds from three investors. In July 2013, GE Ventures invested in BioCEP.

Business overview

BioCEP develops, manufactures, and sells technologies for cell isolation, primarily serving customers in research and development globally. Its core product, the patented Cell Enrichment Process for Isolation of Rare Cells (CEPir) device, enables immunomagnetic cell isolation with high purity and recovery rates. The company is also developing applications for non-invasive prenatal testing and stem cell separation. BioCEP operates within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Industrial Technologies, targeting laboratories and biotechnology segments.

Strategic signal

In July 2013, GE Ventures invested in BioCEP, indicating early validation of the company's cell isolation technology from a major corporate entity. This investment highlighted the potential of BioCEP's CEPir device for research and development applications, signaling investor confidence in its innovative approach to rare cell isolation.

Company Intelligence Q&A

What is BioCEP's primary focus?

BioCEP develops, manufactures, and sells technologies for cell isolation, particularly for research and development applications, utilizing its patented Cell Enrichment Process for Isolation of Rare Cells (CEPir) device.

When was BioCEP founded?

BioCEP was founded in July 2006.

What is the CEPir device?

The CEPir (Cell Enrichment Process for Isolation of Rare Cells) device is BioCEP's patented technology that enables effective immunomagnetic cell isolation for research and development, offering high purity and recovery rates.

What is the current status of BioCEP?

BioCEP is currently non-active and ceased to operate in September 2021.